These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 37434014)

  • 1. Vaccinating the German Population Aged 60 Years and Over with a Quadrivalent High-Dose Inactivated Influenza Vaccine Compared to Standard-Dose Vaccines: A Transmission and Budget Impact Model.
    Pahmeier K; Speckemeier C; Neusser S; Wasem J; Biermann-Stallwitz J
    Pharmacoeconomics; 2023 Nov; 41(11):1539-1550. PubMed ID: 37434014
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness and public health impact of alternative influenza vaccination strategies in high-risk adults.
    Raviotta JM; Smith KJ; DePasse J; Brown ST; Shim E; Nowalk MP; Wateska A; France GS; Zimmerman RK
    Vaccine; 2017 Oct; 35(42):5708-5713. PubMed ID: 28890196
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunogenicity and safety of a quadrivalent high-dose inactivated influenza vaccine compared with a standard-dose quadrivalent influenza vaccine in healthy people aged 60 years or older: a randomized Phase III trial.
    Pepin S; Nicolas JF; Szymanski H; Leroux-Roels I; Schaum T; Bonten M; Icardi G; Shrestha A; Tabar C;
    Hum Vaccin Immunother; 2021 Dec; 17(12):5475-5486. PubMed ID: 34714720
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Superior immunogenicity of high-dose quadrivalent inactivated influenza vaccine versus Standard-Dose vaccine in Japanese Adults ≥ 60 years of age: Results from a phase III, randomized clinical trial.
    Sanchez L; Nakama T; Nagai H; Matsuoka O; Inoue S; Inoue T; Shrestha A; Pandey A; Chang LJ; De Bruijn I;
    Vaccine; 2023 Apr; 41(15):2553-2561. PubMed ID: 36906404
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of seasonal quadrivalent versus trivalent influenza vaccination in the United States: A dynamic transmission modeling approach.
    Brogan AJ; Talbird SE; Davis AE; Thommes EW; Meier G
    Hum Vaccin Immunother; 2017 Mar; 13(3):533-542. PubMed ID: 27780425
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunogenicity and safety of high-dose quadrivalent influenza vaccine in Japanese adults ≥65 years of age: a randomized controlled clinical trial.
    Sanchez L; Matsuoka O; Inoue S; Inoue T; Meng Y; Nakama T; Kato K; Pandey A; Chang LJ
    Hum Vaccin Immunother; 2020 Apr; 16(4):858-866. PubMed ID: 31634025
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness analysis of universal influenza vaccination with quadrivalent inactivated vaccine in the United States.
    Clements KM; Meier G; McGarry LJ; Pruttivarasin N; Misurski DA
    Hum Vaccin Immunother; 2014; 10(5):1171-80. PubMed ID: 24609063
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relative Effectiveness of Adjuvanted Trivalent Inactivated Influenza Vaccine Versus Egg-derived Quadrivalent Inactivated Influenza Vaccines and High-dose Trivalent Influenza Vaccine in Preventing Influenza-related Medical Encounters in US Adults ≥ 65 Years During the 2017-2018 and 2018-2019 Influenza Seasons.
    Boikos C; Fischer L; O'Brien D; Vasey J; Sylvester GC; Mansi JA
    Clin Infect Dis; 2021 Sep; 73(5):816-823. PubMed ID: 33605977
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhanced passive safety surveillance of high-dose and standard-dose quadrivalent inactivated split-virion influenza vaccines in Germany and Finland during the influenza season 2021/22.
    Gandhi-Banga S; Wague S; Shrestha A; Syrkina O; Talanova O; Nissilä M; Stuff K; Monfredo C
    Influenza Other Respir Viruses; 2023 Jan; 17(1):e13071. PubMed ID: 36448240
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High-Dose Inactivated Influenza Vaccine Quadrivalent for Older Adults.
    Chahine EB
    Ann Pharmacother; 2021 Jan; 55(1):89-97. PubMed ID: 32578447
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Seroresponse to Inactivated and Recombinant Influenza Vaccines Among Maintenance Hemodialysis Patients.
    Manley HJ; Lacson EK; Aweh G; Chen Li N; Weiner DE; Miskulin DC; Hsu CM; Kapoian T; Hayney MS; Meyer KB; Johnson DS
    Am J Kidney Dis; 2022 Sep; 80(3):309-318. PubMed ID: 35288216
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and immunogenicity of high doses of quadrivalent influenza vaccine in children 6 months through <18 years of age: A randomized controlled phase II dose-finding trial.
    Chang LJ; Anderson EJ; Jeanfreau R; He Y; Hicks B; Shrestha A; Pandey A; Landolfi V; DeBruijn I;
    Vaccine; 2021 Mar; 39(11):1572-1582. PubMed ID: 33610374
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expected cost effectiveness of high-dose trivalent influenza vaccine in US seniors.
    Chit A; Roiz J; Briquet B; Greenberg DP
    Vaccine; 2015 Jan; 33(5):734-41. PubMed ID: 25444791
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An Assessment of the Expected Cost-Effectiveness of Quadrivalent Influenza Vaccines in Ontario, Canada Using a Static Model.
    Chit A; Roiz J; Aballea S
    PLoS One; 2015; 10(7):e0133606. PubMed ID: 26222538
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-utility analysis of increasing uptake of universal seasonal quadrivalent influenza vaccine (QIV) in children aged 6 months and older in Germany.
    Molnar D; Anastassopoulou A; Poulsen Nautrup B; Schmidt-Ott R; Eichner M; Schwehm M; Dos Santos G; Ultsch B; Bekkat-Berkani R; von Krempelhuber A; Van Vlaenderen I; Van Bellinghen LA
    Hum Vaccin Immunother; 2022 Nov; 18(5):2058304. PubMed ID: 35486410
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety Profile of GSK's Inactivated Quadrivalent Seasonal Influenza Vaccine in Belgium, Germany and Spain: Passive Enhanced Safety Surveillance Study for the 2019/2020 Influenza Season.
    Salamanca de la Cueva I; Cinconze E; Eckermann T; Nwoji U; Godderis L; Lu E; Martínez-Gómez X; Wang H; Yanni E
    Drug Saf; 2021 Dec; 44(12):1375-1390. PubMed ID: 34694589
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and immunogenicity of high-dose quadrivalent influenza vaccine in adults ≥65 years of age: A phase 3 randomized clinical trial.
    Chang LJ; Meng Y; Janosczyk H; Landolfi V; Talbot HK;
    Vaccine; 2019 Sep; 37(39):5825-5834. PubMed ID: 31431411
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influenza burden averted with a cell-based quadrivalent seasonal influenza vaccine compared with egg-based quadrivalent seasonal influenza vaccine.
    McGovern I; Taylor A; Sardesai A; Toro-Diaz H; Haag M
    Expert Rev Vaccines; 2024; 23(1):371-379. PubMed ID: 38494917
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Technical guidelines for seasonal influenza vaccination in China (2022-2023)].
    National Immunization Advisory Committee (NIAC) Technical Working Group (TWG) on Influenza Vaccination
    Zhonghua Yu Fang Yi Xue Za Zhi; 2022 Oct; 56(10):1356-1386. PubMed ID: 36274602
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices - United States, 2022-23 Influenza Season.
    Grohskopf LA; Blanton LH; Ferdinands JM; Chung JR; Broder KR; Talbot HK; Morgan RL; Fry AM
    MMWR Recomm Rep; 2022 Aug; 71(1):1-28. PubMed ID: 36006864
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.